| · Журналы
· Книги
· О проекте
·Электронные версии книг издательства “Атмосфера” поступили в продажу
Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания.
Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru
ИНТЕРНЕТ-МАГАЗИН
|
|
 | |
Нервные болезни
2023 / N 1
Сиалорея как мультидисциплинарная проблема. Обзор возможных причин и терапевтических решений
Д.В. Захаров, Д.Д. Кокарева
Список литературы
1. Гайтон А.К., Холл Дж.Э. Медицинская физиология по Гайтону и Холлу. Пер. с англ. под ред. Кобрина В.И., Галагудзы М.М., Умрюхина А.Е. 2-е изд., испр. и доп. М.: Логосфера; 2018: 923-5.
2. Jost WH, Bäumer T, Laskawi R, Slawek J, Spittau B, Steffen A, Winterholler M, Bavikatte G. Therapy of sialorrhea with botulinum neurotoxin. Neurology & Therapy 2019 Dec;8(2):273-88.
3. Newman Dorland WA. Dorland’s illustrated medical dictionary. Philadelphia, PA: Saunders; 2019. 2144 p.
4. Hockstein NG, Samadi DS, Gendron K, Handler SD. Sialorrhea: a management challenge. American Family Physician 2004 Jun;69(11):2628-34.
5. Scully C, Felix DH. Oral medicine – update for the dental practitioner: dry mouth and disorders of salivation. British Dental Journal 2005 Oct;199(7):423-7.
6. Scully C, Limeres J, Gleeson M, Tomas I, Diz P. Drooling. Journal of Oral Pathology and Medicine 2009 Apr;38(4):321-7.
7. Sialorrhea: a guide to etiology, assessment, and management. In: Salivary glands – new approaches in diagnostics and treatment. Güvenç IA, editor. IntechOpen 2019.
8. Thaxter Nesbeth KA, Samuels LA, Nicholson Daley C, Gossell-Williams M, Nesbeth DA. Ptyalism in pregnancy – a review of epidemiology and practices. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2016 Mar;198:47-9.
9. Suzuki S, Igarashi M, Yamashita E, Satomi M. Ptyalism gravidarum. North American Journal of Medicine and Science 2009 Nov;1(6):303-4.
10. De Braga V, Dahdouh EM, Balayla J. Successful treatment of ptyalism gravidarum with clonidine hydrochloride: a case report. Case Reports in Women’s Health 2022 Apr;34:e00409.
11. Miranda-Rius J, Brunet-Llobet L, Lahor-Soler E, Farré M. Salivary secretory disorders, inducing drugs, and clinical management. International Journal of Medical Sciences 2015 Sep;12(10):811-24.
12. Волкова М.Н., Чернявский Ю.П., Сахарук Н.А., Еленская Ю.Р. Заболевания слизистой оболочки рта. Учебно-методическое пособие. Витебск: ВГМУ; 2016. 236 с.
13. Szabadi E, Tavernor S. Hypo- and hypersalivation induced by psychoactive drugs. CNS Drugs 1999 Jun;11(6):449-66.
14. Михайлов В.А., Захаров Д.В., Хубларова Л.А. Стратификация риска развития поздних лекарственно-индуцированных осложнений. Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева 2017;4:111-4.
15. Freudenreich O. Drug-induced sialorrhea. Drugs of Today (Barcelona, Spain: 1998) 2005 Jun;41(6):411-8.
16. Szabadi E. Clozapine-induced hypersalivation. The British Journal of Psychiatry 1997 Jul;171:89.
17. Bird AM, Smith TL, Walton AE. Current treatment strategies for clozapine-induced sialorrhea. The Annals of Pharmacotherapy 2011 May;45(5):667-75.
18. Man WH, Wilting I, Souverein P, Meyboom R, Egberts T, Heerdink ER. Reporting patterns of sialorrhea comparing users of clozapine to users of other antipsychotics: a disproportionality analysis using VigiBase. Journal of Clinical Psychopharmacology 2020 May-Jun;40(3):283-6.
19. Vinayak V, Annigeri RG, Patel HA, Mittal S. Adverse affects of drugs on saliva and salivary glands. Journal of Orofacial Sciences 2013 Jan;5(1):15-20.
20. Steele LS, Glazier RH. Is donezepil effective for treating Alzheimer’s disease? Canadian Family Physician 1999 Apr;45:917-9.
21. Kales SN, Christiani DC. Acute chemical emergencies. The New England Journal of Medicine 2004 Feb;350(8):800-8.
22. Brown JS Jr. Environmental and chemical toxins and psychiatric illness. Washington, DC: American Psychiatric Publishing; 2002. 320 p.
23. Clarkson TW, Magos L, Myers GJ. The toxicology of mercury – current exposures and clinical manifestations. The New England Journal of Medicine 2003 Oct;349(18):1731-7.
24. Solis MT, Yuen E, Cortez PS, Goebel PJ. Family poisoned by mercury vapor inhalation. The American Journal of Emergency Medicine 2000 Sep;18(5):599-602.
25. Koury R, Warrington SJ. Rabies. In: StatPearls [Internet]. Treasure Island. 2022 Jan. Last update: 2022 Oct 31. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448076/ Accessed 2023 Apr 11.
26. Nicholson KG. Human rabies. In: Handbook of neurovirology. McKendall RR, Stroop WG, editors. New York, NY: Marcel Dekker; 1994: 463-80.
27. Климова Е.А., Ющук Н.Д. Бешенство. Инфекционные болезни. Национальное руководство. М.: Гэотар-Медиа; 2009: 888-96.
28. Патологическая физиология. Учебник. Под общ. ред. Моррисона В.В., Чесноковой Н.П. 4-е изд. Саратов: Издательство Саратовского государственного медицинского университета; 2009. 679 с.
29. Залялова З.А. Гиперсаливация при болезни Паркинсона: причины и возможности лечения. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски 2015;115(10-2):71-7.
30. Melvin JE, Yule D, Shuttleworth T, Begenisich T. Regulation of fluid and electrolyte secretion in salivary gland acinar cells. Annual Review of Physiology 2005;67:445-69.
31. Mechanisms of salivary secretion. In: Saliva and oral health. Smith PM. Edgar M, Dawes C, O’Mullane D, editors. 4th ed. London: Stephen Hancocks; 2012: 17-36.
32. Boyce HW, Bakheet MR. Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease. Journal of Clinical Gastroenterology 2005 Feb;39(2):89-97.
33. Nicaretta DH, de Rosso AL, Maliska C, Costa MM. Scintigraphic analysis of the parotid glands in patients with sialorrhea and Parkinson’s disease. Parkinsonism & Related Disorders 2008;14(4):338-41.
34. Erasmus C E, Van Hulst K, Rotteveel LJ, Jongerius PH, Van Den Hoogen FJ, Roeleveld N, Rotteveel JJ. Drooling in cerebral palsy: hypersalivation or dysfunctional oral motor control? Developmental Medicine & Child Neurology 2009 Jun;51(6):454-9.
35. Barbero P, Busso M, Artusi CA, De Mercanti S, Tinivella M, Veltri A, Durelli L, Clerico M. Ultrasound-guided botulinum toxin-A injections: a method of treating sialorrhea. Journal of Visualized Experiments 2016 Nov;117:54606.
36. Taib BG, Williams SP, Sood S, Ung K, Nixon PP, Sharma R. Treatment of sialorrhea with repeated ultrasound-guided injections of botulinum toxin A into the parotid and submandibular glands. The British Journal of Oral & Maxillofacial Surgery 2019 Jun;57(5):442-8.
37. Abboud WA, Nadel S, Hassin-Baer S, Arad A, Dobriyan A, Yahalom R. Ultrasound-guided botulinum toxin injections into the salivary glands for the treatment of drooling. The Israel Medical Association Journal 2019 Feb;21(2):116-9.
38. Meningaud JP, Pitak-Arnnop P, Chikhani L, Bertrand JC. Drooling of saliva: a review of the etiology and management options. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 2006 Jan;101(1):48-57.
39. Nunn JH. Drooling: review of the literature and proposals for management. Journal of Oral Rehabilitation 2000 Sep;27(9):735-43.
40. Morgante F, Bavikatte G, Anwar F, Mohamed B. The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®). Therapeutic Advances in Neurological Disorders 2019 Nov;12:1756286419888601.
41. Isaacson SH, Ondo W, Jackson CE, Trosch RM, Molho E, Pagan F, Lew M, Dashtipour K, Clinch T, Espay AJ; MYSTICOL Study Group. Safety and efficacy of rimabotulinumtoxinB for treatment of sialorrhea in adults: a randomized clinical trial. JAMA Neurology 2020 Apr;77(4):461-9.
42. Bartolome G. Grundlagen der funktionellen Dysphagietherapie (FDT). In: Bartolome G, Schröter-Morasch H, editors. Schluckstörungen – Diagnostik und Rehabilitation. Munich; Jena: Urban & Fischer; 2010: 245-370.
43. Prosiegel M, Bartolome G, Biniek R, Fheodoroff K, Schlaegel W, Schröter-Morasch H, Saltuari U. Rehabilitation neurogener Dysphagien. In: Diener HC, editor. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme; 2008: 908-19.
44. Hinchey JA, Shephard T, Furie K, Smith D, Wang D, Tonn S; Stroke Practice Improvement Network Investigators. Formal dysphagia screening protocols prevent pneumonia. Stroke 2005 Sep;36(9):1972-6.
45. Carnaby G, Hankey GJ, Pizzi J. Behavioural intervention for dysphagia in acute stroke: a randomised controlled trial. The Lancet. Neurology 2006 Jan;5(1):31-7.
46. Hussein I, Kershaw AE, Tahmassebi JF, Fayle SA. The management of drooling in children and patients with mental and physical disabilities: a literature review. International Journal of Paediatric Dentistry 1998 Mar;8(1):3-11.
47. Limbrock GJ, Hoyer H, Scheying H. Drooling, chewing and swallowing dysfunctions in children with cerebral palsy: treatment according to Castillo-Morales. ASDC Journal of Dentistry for Children 1990 Nov-Dec;57(6):445-51.
48. De Simone GG, Eisenchlas JH, Junin M, Pereyra F, Brizuela R. Atropine drops for drooling: a randomized controlled trial. Palliative Medicine 2006 Oct;20(7):665-71.
49. Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Movement Disorders 2002 Nov;17(6):1318-20.
50. Matos Santana TE, Capurso NA, Ranganathan M, Yoon G. Sublingual atropine in the treatment of clozapine-induced sialorrhea. Schizophrenia Research 2017 Apr;182:144-5.
51. Fischbacher L, Schröter-Morasch H. Medikamentöse Speichelreduktion bei Neurogener Dysphagie. In: Gross M, Kruse E, editors. Aktuelle phoniatrische-pädaudiologische Aspekte 2003/2004 Band 11. Niebüll: Medicombooks.de. im Verlag Videel.
52. Man WH, Colen-de Koning JC, Schulte PF, Cahn W, van Haelst IM, Doodeman HJ, Egberts TC, Heerdink ER, Wilting I. The effect of glycopyrrolate on nocturnal sialorrhea in patients using clozapine: a randomized, crossover, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 2017 Apr;37(2):155-61.
53. Lee ZI, Yu KJ, Lee DH, Hong SK, Woo SB, Kim JM, Park D. The effect of nebulized glycopyrrolate on posterior drooling in patients with brain injury: two cases of different brain lesions. American Journal of Physical Medicine & Rehabilitation 2017 Aug;96(8):e155-8.
54. Fairhurst CB, Cockerill H. Management of drooling in children. Archive of Disease in Childhood. Education and Practice Edition 2011 Feb;96(1):25-30.
55. Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M. Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study. Archives of Pediatrics & Adolescent Medicine 2000 Dec;154(12):1214-8.
56. Crysdale WS, White A. Submandibular duct relocation for drooling: a 10-year experience with 194 patients. Otolaryngology – Head and Neck Surgery 1989 Jul;101(1):87-92.
57. Kok SE, van der Burg JJ, van Hulst K, Erasmus CE, van den Hoogen FJ. The impact of submandibular duct relocation on drooling and the well-being of children with neurodevelopmental disabilities. International Journal of Pediatric Otorhinolaryngology 2016 Sep;88:173-8.
58. Feussner H, Schröter-Morasch H. Chirurgische Interventionen bei Schluckstörungen. In: Schluckstörungen – Diagnostik und Rehabilitation. Bartolome G, Schröter-Morasch H, editors. 5th ed. Munich: Elsevier; 2014.
59. Lawson G, Remacle M. Endoscopic cricopharyngeal myotomy: indications and technique. Current Opinion in Otolaryngology & Head and Neck Surgery 2006 Dec;14(6):437-41.
60. Martin TJ, Conley SF. Long-term efficacy of intra-oral surgery for sialorrhea. Otolaryngology – Head and Neck Surgery 2007 Jul;137(1):54-8.
61. Reed J, Mans CK, Brietzke SE. Surgical management of drooling: a meta-analysis. Archives of Otolaryngology, Head and Neck Surgery 2009 Sep;135(9):924-31.
62. Noonan K, Prunty S, Ha JF, Vijayasekaran S. Surgical management of chronic salivary aspiration. International Journal of Pediatric Otorhinolaryngology 2014 Dec;78(12):2079-82.
63. Seegenschmiedt MH, Makoski HB, Trott KR, Brady LW. Sialorrhea/hypersalivation. In: Radiotherapy for non-malignant disorders. Seegenschmiedt MH, Makoski HB, Trott KR, Brady LW, editors. Berlin: Springer; 2008: 573-9.
64. Andersen PM, Grönberg H, Franzen L, Funegård U. External radiation of the parotid glands significantly reduces drooling in patients with motor neuron disease with bulbar paresis. Journal of the Neurological Sciences 2001 Oct;191(1-2):111-4.
65. Borg M, Hirst F. The role of radiation therapy in the management of sialorrhea. International Journal of Radiation Oncology, Biology, Physics 1998 Jul;41(5):1113-9.
66. Neppelberg E, Haugen DF, Thorsen L, Tysnes OB. Radiotherapy reduces sialorrhea in amyotrophic lateral sclerosis. European Journal of Neurology 2007 Dec;14(12):1373-7.
67. Postma AG, Heesters M, van Laar T. Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Movement Disorders 2007 Dec;22(12):2430-5.
68. Assouline A, Levy A, Abdelnour-Mallet M, Gonzalez-Bermejo J, Lenglet T, Le Forestier N, Salachas F, Bruneteau G, Meininger V, Delanian S, Pradat PF. Radiation therapy for hypersalivation: a prospective study in 50 amyotrophic lateral sclerosis patients. International Journal of Radiation Oncology, Biology, Physics 2014 Mar;88(3):589-95.
69. Hawkey NM, Zaorsky NG, Galloway TJ. The role of radiation therapy in the management of sialorrhea: a systematic review. The Laryngoscope 2016 Jan;126(1):80-5.
70. Christiansen H, Wolff HA, Knauth J, Hille A, Vorwerk H, Engelke C, Rödel R, Laskawi R. [Radiotherapy: an option for refractory salivary fistulas.] HNO 2009 Dec;57(12):1325-8.
71. Weikamp JG, Schinagl DA, Verstappen CC, Schelhaas HJ, de Swart BJ, Kalf JG. Botulinum toxin-A injections vs. radiotherapy for drooling in ALS. Acta Neurologica Scandinavica 2016 Sep;134(3):224-31.
72. Xu H, Shan XF, Cong X, Yang NY, Wu LL, Yu GY, Zhang Y, Cai ZG. Pre- and post-synaptic effects of botulinum toxin A on submandibular glands. Journal of Dental Research 2015 Oct;94(10):1454-62.
73. Bushara KO. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment – botulinum toxin A injections of the parotid glands. Medical Hypotheses 1997 Apr;48(4):337-9.
74. Bhatia KP, Münchau A, Brown P. Botulinum toxin is a useful treatment in excessive drooling in saliva. Journal of Neurology, Neurosurgery & Psychiatry 1999 Nov;67(5):697.
75. Jost WH. Treatment of drooling in Parkinson’s disease with botulinum toxin. Movement Disorders 1999 Nov;14(6):1057.
76. Verma R, Anand KS. Botulinum toxin: a novel therapy for clozapine-induced sialorrhoea. Psychopharmacology 2018 Jan;235(1):369-71.
77. Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, Pacchetti C. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Movement Disorders 2003 Jun;18(6):685-8.
78. Martínez-Poles J, Nedkova-Hristova V, Escribano-Paredes JB, García-Madrona S, Natera-Villalba E, Estévez-Fraga C, López-Sendón Moreno JL, Avilés-Olmos I, Sánchez Díaz G, Martínez Castrillo JC, Alonso-Canovas A. Incobotulinumtoxin A for sialorrhea in neurological disorders: a real-life experience. Toxins 2018 May;10(6):217.
79. Narayanaswami P, Geisbush T, Tarulli A, Raynor E, Gautam S, Tarsy D, Gronseth G. Drooling in Parkinson’s disease: a randomized controlled trial of incobotulinum toxin A and meta-analysis of botulinum toxins. Parkinsonism & Related Disorders 2016 Sep;30:73-7.
80. Restivo DA, Panebianco M, Casabona A, Lanza S, Marchese-Ragona R, Patti F, Masiero S, Biondi A, Quartarone A. Botulinum toxin A for sialorrhoea associated with neurological disorders: evaluation of the relationship between effect of treatment and the number of glands treated. Toxins 2018 Jan;10(2):55.
81. Stokholm MG, Bisgård C, Vilholm OJ. Safety and administration of treatment with botulinum neurotoxin for sialorrhoea in ALS patients: review of the literature and a proposal for tailored treatment. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 2013 Dec;14(7-8):516-20.
82. Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, Reiners C, Toyka KV. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 2000 Jul;69(1):121-3.
83. Cisneros-Lesser JC, Hernández-Palestina MS. Treatment of patients with sialorrhea. A systematic review. Investigación en Discapacidad 2017;6(1):17-24.
84. Ko SH, Shin YB, Min JH, Shin MJ, Chang JH, Shin YI, Ko HY. Botulinum toxin in the treatment of drooling in tetraplegic patients with brain injury. Annals of Rehabilitation Medicine 2013 Dec;37(6):796-803.
85. Mazlan M, Rajasegaran S, Engkasan JP, Nawawi O, Goh KJ, Freddy SJ. A double-blind randomized controlled trial investigating the most efficacious dose of botulinum toxin-A for sialorrhea treatment in Asian adults with neurological diseases. Toxins 2015 Sep;7(9):3758-70.
86. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology 2004 Jan;62(1):37-40.
87. Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson’s disease: a prospective double-blind trial. Movement Disorders 2012 Feb;27(2):219-26.
88. Guidubaldi A, Fasano A, Ialongo T, Piano C, Pompili M, Mascianà R, Siciliani L, Sabatelli M, Bentivoglio AR. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson’s disease. Movement Disorders 2011 Feb;26(2):313-9.
89. Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, McVey A, Kittrell PP, King R, Herbelin L; Muscle Study Group. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle & Nerve 2009 Feb;39(2):137-43.
90. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Movement Disorders 2006 May;5:704-7.
91. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Long-lasting benefits of botulinum toxin type B in Parkinson’s disease-related drooling. Journal of Neurology 2009 Apr;256(4):563-7.
92. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003 Nov;61(9):1279-81.
93. Reid SM, Johnstone BR, Westbury C, Rawicki B, Reddihough DS. Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders. Development Medicine & Child Neurology 2008 Feb;50(2):123-8.
94. Jost W, Friedman A, Michel O, Oehlwein C, Slawek J, Bogucki A, Ochudlo S, Banach M, Pagan F, Flatau-Baqué B, Csikós J, Cairney CJ, Blitzer A. SIAXI: placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology 2019 Apr;92(17):e1982-91. |
[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ] |
|
|
